Press Room

The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news from our CMTA-STAR Alliance Partner, Applied Therapeutics. The company plans to submit a New Drug Application (NDA) to the FDA for govorestat to treat CMT-SORD ...

The Charcot-Marie-Tooth Association (CMTA) has announced a $240K investment in a groundbreaking gene replacement therapy for CMT4A, with potential applications for other types of CMT. This critical project is led by Xin Chen, MD, PhD, ...

In a groundbreaking three-year joint project between the Charcot-Marie-Tooth Association (CMTA) and the Muscular Dystrophy Association (MDA), researchers led by Alexia Kagiava, PhD, at the Cyprus Institute of Neurology and Genetics are pioneering the use ...

Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form of CMT, caused by having an extra copy of the PMP22 gene. This results in PMP22 overexpression, leading to excessive PMP22 protein in Schwann cells, ...

Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Association (CMTA) and its Strategy To Accelerate Research (STAR) and led by CMTA-STAR Advisory Board member Mario Saporta, MD, PhD, have made significant progress in ...